A Phase 1 interventional study of Ia:QLS2404 very low dose and Ia:QLS2404 low dose in Systemic Lupus Erythematosus and Primary Sjögren's Syndrome, sponsored by Qilu Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-07.
Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 266 studies in Lupus Erythematosus, Systemic with a site in China — 168 open to participants now, 191 under way, 22 of them phase 3. Lupus Erythematosus, Systemic · China.
Among the 266 studies in Lupus Erythematosus, Systemic with a site in China, this one is the 87th largest by planned enrollment of the 245 interventional ones that give a count, is one of 56 that started in 2026, is one of 109 in phase 1, reaches primary completion later than 122 of the 190 other live ones, and was the 261st registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →168 of the 266 studies in Lupus Erythematosus, Systemic with a site in China are open now. Recruiting first, the newest first:
Genentech, Inc. · Sites in China, Australia, Brazil and 3 more countries
Ages 18–75
Antengene Biologics Limited · Sites in China
Ages 18+
AstraZeneca · Sites in China, United States, Argentina and 32 more countries
Ages 5–80
AstraZeneca · Sites in China
Ages 18–70
Peking Union Medical College Hospital · Sites in China
Ages 6–18
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
266 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 128 · Phase 2 56 · Phase 3 36 · Phase 4 16
First in 2006; this study’s year is marked. 56 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 64 is above the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 36 across the 245 interventional studies, 180 across the 21 observational. Of the 54 that completed or were terminated, 25 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
133 of 266 have an industry lead sponsor. The 10 most frequent:
Qilu Pharmaceutical Co., Ltd. is the lead sponsor of 200 studies on the registry; 122 are open to participants now.
Qilu Pharmaceutical Co., Ltd. has 3 studies filed under Lupus Erythematosus, Systemic — fewer than ten, so there is no comparison to draw.
58 of the studies in Lupus Erythematosus, Systemic with a site in China that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05138133Phase 3AstraZenecaPhase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | 2027-02-23 |
| NCT05843643Phase 3AbbVieProgram to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus | 2027-03 |
| NCT05639114Phase 3Novartis PharmaceuticalsPhase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1) | 2027-03-26 |
| NCT05126277Phase 3Novartis PharmaceuticalsSafety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis | 2027-09-21 |
| NCT07657793Phase 3Chinese SLE Treatment And Research GroupSirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia | 2027-09-30 |
Add all 58 to your calendar (.ics) → With an account.
Among the 266 studies in Lupus Erythematosus, Systemic with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study consists of a randomized, double-blind, placebo-controlled Phase Ia part and an open-label Phase Ib part. The Phase Ia part is a single ascending-dose study of subcutaneous QLS2404 Injection in healthy participants, designed to evaluate the safety and tolerability of QLS2404 Injection in healthy participants. The Phase Ib part is a multiple ascending-dose study of subcutaneous QLS2404 Injection in participants with systemic lupus erythematosus and primary Sjögren's syndrome, designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of QLS2404 Injection.
The Phase Ia single-dose ascending stage will include five dose groups. The study plans to enroll 40 adult healthy participants, with 8 participants in each dose group, who will be randomized in a 3:1 ratio to receive QLS2404 Injection or placebo. Dose escalation will be conducted sequentially from the initial dose to higher dose levels in accordance with the dose-escalation principle.
During the study, a Safety Monitoring Committee (SMC), composed of the investigators, the sponsor, or sponsor-designated personnel, will review the safety data generated during the trial. After the last participant in each dose group has completed the 14-day tolerability observation period following dosing, the SMC will review the safety data of participants in each cohort and conduct an integrated assessment of the available pharmacokinetic (PK) and pharmacodynamic (PD) data. The SMC will then provide recommendations regarding dose escalation or, if necessary, adjustments to the dose-escalation scheme.
The Phase Ib part will be a multiple ascending-dose study of subcutaneous QLS2404 Injection in participants with systemic lupus erythematosus (SLE) and primary Sjögren's syndrome (pSS), designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of QLS2404 Injection. Three dose groups are planned, with approximately 24 participants to be enrolled in total and 8 participants in each dose group. All participants will receive three subcutaneous doses of QLS2404 Injection, administered at 4-week intervals. Each dose group must include at least 6 participants with SLE, and the study will be conducted in strict accordance with the dose-escalation principle.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Ia:QLS2404 very low dose
Drug: Ia:QLS2404 low dose
Drug: Ia:QLS2404 middle dose
Drug: Ia:QLS2404 high dose
Drug: Ia:QLS2404 Max dose
Drug: Ib:QLS2404 low dose
Drug: Ib:QLS2404 middle dose
Drug: Ib:QLS2404 high dose
a single subcutaneous dose of QLS2404 Injection in healthy participants
a single subcutaneous dose of QLS2404 Injection in healthy participants
a single subcutaneous dose of QLS2404 Injection in healthy participants
a single subcutaneous dose of QLS2404 Injection in healthy participants
a single subcutaneous dose of QLS2404 Injection in healthy participants
multiple subcutaneous doses of QLS2404 Injection in participants with systemic lupus erythematosus (SLE) and primary Sjögren's syndrome (pSS)
multiple subcutaneous doses of QLS2404 Injection in participants with systemic lupus erythematosus (SLE) and primary Sjögren's syndrome (pSS)
multiple subcutaneous doses of QLS2404 Injection in participants with systemic lupus erythematosus (SLE) and primary Sjögren's syndrome (pSS)
Ia:the safety and tolerability of a single subcutaneous dose of QLS2404 Injection in healthy participants
Number of participants with Adverse events and Serious adverse events
Time frame: from the first single subcutaneous Inject of QLS2404 up to Day85
Ib:To evaluate the Adverse events of multiple subcutaneous injections of QLS2404 Injection in participants with systemic lupus erythematosus (SLE) and primary Sjögren's syndrome (pSS).
Number of participants with Adverse events and Serious adverse events
Time frame: from the first single subcutaneous Inject of QLS2404 up to Day141.
Ia Outcome 1:To evaluate the pharmacokinetic (PK) characteristics of a single subcutaneous injection of QLS2404 Injection in healthy participants.
include serum QLS2404 concentrations such as peak plasma concentration (Cmax)
Time frame: from the first single subcutaneous Inject of QLS2404 up to Day85
Ia Outcome 2:To evaluate the pharmacodynamic (PD) characteristics of a single subcutaneous injection of QLS2404 Injection in healthy participants.
assessments include serum levels of IgM, IgG, and IgA at each scheduled time point before and after dosing
Time frame: from the first single subcutaneous Inject of QLS2404 up to Day85.
Ia Outcome 3:To evaluate the immunogenicity of a single subcutaneous injection of QLS2404 Injection in healthy participants.
include the incidence and titers of anti-drug antibodies (ADAs) against QLS2404 Injection in healthy participants, and the incidence of neutralizing antibodies (NAbs), if data permit.
Time frame: from the first single subcutaneous Inject of QLS2404 up to Day85
Ib Outcome 1:Applicable to participants with SLE: The proportion of participants with a ≥ 4-point decrease from baseline in SLE Disease Activity Index 2000 (SLEDAI-2K).
SLEDAI-2K Description: The minimum SLEDAI-2K score is 0, and the maximum theoretical SLEDAI-2K score is 105. A score of 0 indicates no active disease; a greater score indicates higher systemic lupus erythematosus disease activity.
Time frame: from the first subcutaneous Inject of QLS2404 up to Day141.
Ib Outcome 2:To evaluate the pharmacokinetic (PK) characteristics of multiple subcutaneous injections of QLS2404 Injection in participants .
Serum drug concentrations after administration peak plasma concentration (Cmax)
Time frame: from the first subcutaneous Inject of QLS2404 up to Day141
Ib Outcome 3:Evaluate the PD characteristics of multiple subcutaneous injections of QLS2404 Injection in participants with SLE and pSS;
Serum IgM, IgG, and IgA levels at each assessment time point, and the percentage change from baseline;
Time frame: from the first subcutaneous Inject of QLS2404 up to Day141
Ib Outcome 4:Evaluate the immunogenicity of multiple subcutaneous injections of QLS2404 Injection in participants with SLE and pSS;
Incidence and titers of anti-drug antibodies (ADA) to QLS2404 Injection in participants with SLE and pSS; incidence of neutralizing antibodies (NAb), if data permit.
Time frame: from the first subcutaneous Inject of QLS2404 up to Day141
Applicable to participants with pSS: The proportion of participants with a ≥ 3-point ESSDAI
Description: The minimum ESSDAI score is 0, and the maximum ESSDAI score is 123. A score of 0 indicates no systemic disease activity; a greater score indicates higher systemic disease activity in Sjögren's syndrome.
Time frame: from the first subcutaneous Inject of QLS2404 up to Day141.
Start is estimated for Aug 2026; primary completion for Nov 2027, 14 months later.
Of 108 industry-sponsored phase 1 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's planned 14 months is below that.
Counting every sponsor, half of 147 studies reached it within 28 months; a quarter within 16 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lupus Erythematosus, Systemic →
Qilu Pharmaceutical Co., Ltd. →